Ireland - English - HPRA (Health Products Regulatory Authority)

cephalon uk limited - capsaicin - cream - 0.075 percent weight/weight - capsaicin and similar agents; capsaicin

Ireland - English - HPRA (Health Products Regulatory Authority)

cephalon uk limited - capsaicin - cream - 0.025 percent weight/weight - capsaicin and similar agents; capsaicin

Canada - English - Health Canada

wex pharmaceuticals inc - capsaicin - cream - 0.025% - capsaicin 0.025% - basic lotions and liniments

Canada - English - Health Canada

wex pharmaceuticals inc - capsaicin - cream - 0.05% - capsaicin 0.05% - basic lotions and liniments

Canada - English - Health Canada

wex pharmaceuticals inc - capsaicin - cream - 0.075% - capsaicin 0.075% - basic lotions and liniments

Canada - English - Health Canada

ferndale laboratories inc. - capsaicin - cream - .025% - capsaicin .025% - basic lotions and liniments

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - capsaicin - cream - 0.025 percent weight/weight - capsaicin and similar agents

United States - English - NLM (National Library of Medicine)

pharmaplast sae - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - capsaicin 0.6 mg - topical analgesic temporarily relieves minor pain associated with: - arthritis - simple backache - strains - sprains - bruises - on wounds or damaged skin - with or at the same time as other external analgesic products - conditions worsens - symptoms persist more than 7 days or clear up and occur again within a few days - rash, itching or excessive skin irritation develops

Canada - English - Health Canada

vivier medical inc. - capsaicin - cream - 0.05% - capsaicin 0.05% - basic lotions and liniments

United States - English - NLM (National Library of Medicine)

acorda therapeutics, inc. - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - capsaicin 640 ug in 1 cm2 - qutenza is indicated for the management of neuropathic pain associated with postherpetic neuralgia. none. teratogenic effects: pregnancy category b there are no adequate and well-controlled studies evaluating qutenza in pregnant women. there was no evidence of fetal teratogenicity in embryofetal developmental toxicological studies conducted in pregnant rats and rabbits in which qutenza patches (rats) or liquid (rabbits) were applied once daily for a 3 hour duration during the period of fetal organogenesis up to doses corresponding to an 11-fold (rat, 32 mg capsaicin patch/day) and 37-fold (rabbit, 260 mg capsaicin/day) margin over the maximum recommended human dose [mrhd] based on a c max exposure comparison. in a peri- and post-natal reproduction toxicology study, pregnant female rats were treated with qutenza patches at doses up to 32 mg capsaicin patch/rat/day applied once daily for a 3 hours duration during gestation and lactation (from gestation day 7 through day 28 postpartum). analyses of milk samples